Patents by Inventor Yoko Shibata

Yoko Shibata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240052017
    Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.
    Type: Application
    Filed: April 21, 2023
    Publication date: February 15, 2024
    Applicant: HEPTARES THERAPEUTICS LIMITED
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
  • Patent number: 11673938
    Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: June 13, 2023
    Assignee: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
  • Publication number: 20220403048
    Abstract: An isolated antigen-binding protein characterised in that it is capable of binding specifically to human Arginase II (ARG2) and inhibiting the enzyme activity of human ARG2.
    Type: Application
    Filed: August 21, 2020
    Publication date: December 22, 2022
    Applicants: Cancer Research Technology Limited, Medimmune Limited
    Inventors: Alexandra Addyman, Mark Austin, Michelle Barnard, Vincenzo Cerundolo, Denice Chan, Agata Diamandakis, Sebastian Fielder, Maria Groves, Stuart Haynes, Sarah Holt, Lesley Jenkinson, Stephanie Keswick, Fiona McLaughlin, Pooja Sharma, Yoko Shibata, Louise Slater, Jessica Whitehouse, Mark D Carr, Daniel Burschowsky, Chitra Seewooruthun
  • Publication number: 20210148939
    Abstract: A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular formation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed.
    Type: Application
    Filed: November 30, 2020
    Publication date: May 20, 2021
    Applicant: Heptares Therapeutics Limited
    Inventors: Malcolm Peter Weir, Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne
  • Publication number: 20210061882
    Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.
    Type: Application
    Filed: May 11, 2020
    Publication date: March 4, 2021
    Applicant: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
  • Publication number: 20200247885
    Abstract: The invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.
    Type: Application
    Filed: April 6, 2020
    Publication date: August 6, 2020
    Inventors: Wendy A. WILLIAMS, Clare JONES, James BUTTON, John LINLEY, Harm Jan SNIJDER, Ling HUANG, Yoko SHIBATA, Sudharsan SRIDHARAN, Maria GROVES, Claire DOBSON
  • Patent number: 10654926
    Abstract: The invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.
    Type: Grant
    Filed: May 2, 2015
    Date of Patent: May 19, 2020
    Assignee: MedImmune Limited
    Inventors: Wendy A Williams, Clare Jones, James Button, John Linley, Harm Jan Snijder, Ling Huang, Yoko Shibata, Sudharsan Sridharan, Maria Groves, Claire Dobson
  • Publication number: 20190241644
    Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.
    Type: Application
    Filed: December 10, 2018
    Publication date: August 8, 2019
    Applicant: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
  • Publication number: 20190094247
    Abstract: A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular formation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed.
    Type: Application
    Filed: October 4, 2018
    Publication date: March 28, 2019
    Applicant: Heptares Therapeutics Limited
    Inventors: Malcolm Peter Weir, Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne
  • Patent number: 10126313
    Abstract: A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular formation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: November 13, 2018
    Assignee: Heptares Therapeutics Limited
    Inventors: Malcolm Peter Weir, Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne
  • Publication number: 20180086814
    Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.
    Type: Application
    Filed: September 26, 2017
    Publication date: March 29, 2018
    Applicant: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
  • Publication number: 20170166634
    Abstract: The invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.
    Type: Application
    Filed: May 2, 2015
    Publication date: June 15, 2017
    Applicant: Medimmune Limited
    Inventors: Wendy A WILLIAMS, Clare JONES, James BUTTON, John LINLEY, Harm Jan SNIJDER, Ling HUANG, Yoko SHIBATA, Sudharsan SRIDHARAN, Maria GROVES, Claire DOBSON
  • Publication number: 20160052991
    Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.
    Type: Application
    Filed: August 26, 2015
    Publication date: February 25, 2016
    Applicant: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
  • Patent number: 8785135
    Abstract: The present invention relates in some aspects to mutant G protein coupled receptors (GPCRs) and methods for selecting those with increased stability. In certain aspects, the invention relates to the selection and preparation of mutant GPCRs which have increased stability under a particular condition compared to their respective parent proteins.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: July 22, 2014
    Assignee: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
  • Publication number: 20120270230
    Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.
    Type: Application
    Filed: June 11, 2012
    Publication date: October 25, 2012
    Applicant: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Wame, Malcolm Peter Weir
  • Publication number: 20100190188
    Abstract: A method for selecting a G-protein coupled receptor (GPCR) with increased stability, the method comprising (a) providing one or more mutants of a parent GPCR, (b) selecting a ligand, the ligand being one which hinds to the parent GPCR when the GPCR is residing in a particular conformation, (c) determining whether the or each mutant GPCR has increased stability with respect to binding the selected ligand compared to the stability of the parent GPCR with respect to binding that ligand, and (d) selecting those mutants that have an increased stability compared to the parent GPCR with respect to binding the selected ligand. Mutants of ?-adrenergic receptor, adenosine receptor and neurotensin receptor are also disclosed.
    Type: Application
    Filed: March 20, 2008
    Publication date: July 29, 2010
    Applicant: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir